IBI Ag secures $6.1 million to bring pharma-inspired crop protection to farms
The company’s single-domain antibody technology aims to redefine sustainable agriculture.
IBI Ag, a crop protection company that develops a wide array of bio-insecticides with a lower ecological footprint, announced that it has closed the first part of its Series A funding round with a $6.1 million investment. The round was led by Corteva, Inc., through its Corteva Catalyst platform, with participation from The Trendlines Group, Iron Nation, Consensus Business Group, and a grant from the Israel Innovation Authority.
IBI Ag has developed technology that leverages single-domain antibodies to produce highly effective crop protection solutions with a low ecological footprint. This technology—adapted from the pharmaceutical industry and modified for the agricultural market—introduces novel modes of action and represents a new approach to protecting crops from insects. The products under development target a broad spectrum of pests, including both sucking and chewing insects, while minimizing the impact on non-target organisms. The company is initially focusing on high-value crops, with plans to expand into row crops.
“This investment will help us accelerate the development of our single-domain antibody technology, providing farmers with sustainable and effective crop protection solutions,” said Arnon Heyman, CEO of IBI Ag. “We believe our single-domain antibody technology is a game changer for driving agricultural productivity while preserving the environment.”
IBI Ag was established by The Trendlines Group, together with founders Amir Ayali, PhD, and Rony Oren Benaroya, PhD, with support from the Israel Innovation Authority.
